Onesource Specialty Pharma Q2 Results: Stock jumps 8% on strong operating performance, revenue growth

Shares of OneSource Specialty Pharma Ltd., the demerged entity of Strides Pharma, along with the CDMO business of Steriscience Specialties Pvt. Ltd., surged as much as 8% on Tuesday, October 27, in response to its September quarter results, which were strong on an operational basis compared to the base quarter.

Net profit for the period increased to ₹57.4 crore from ₹10.4 crore last year. The growth in profitability was aided by a healthy revenue performance and margin expansion.

Onesource reported revenue of ₹516.2 crore, which is a growth of 37.4% from the same quarter last year, when it had reported a figure of ₹376 crore.

Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹163.2 crore, a 53% year-on-year jump from ₹107 crore it reported during the year-ago quarter.

EBITDA margin expanded by over 300 basis points from last year to 31.6% from 28.4% on a year-on-year basis.

Shares of Onesource began trading on the bourses in January 2025 at a price of ₹1,800 per share, a 6.9% to its pre-open discovery price. The stock is currently trading 6.4% higher on Tuesday after the results announcement, at ₹1,486.1. The stock is still down 23% from its recent 52-week high of ₹1,925.

This story will be updated with more details.